ECSP013952A - Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina - Google Patents

Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Info

Publication number
ECSP013952A
ECSP013952A EC2001003952A ECSP013952A ECSP013952A EC SP013952 A ECSP013952 A EC SP013952A EC 2001003952 A EC2001003952 A EC 2001003952A EC SP013952 A ECSP013952 A EC SP013952A EC SP013952 A ECSP013952 A EC SP013952A
Authority
EC
Ecuador
Prior art keywords
oral administration
ciprofloxacine
administration system
daily intake
controlled oral
Prior art date
Application number
EC2001003952A
Other languages
English (en)
Inventor
Naresh Talwar
John N Staniforth
Ashok Rampal
Gour Mukherji
N Bradi Vishwanathan
Brij Khera
Original Assignee
Ranbaxy Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd filed Critical Ranbaxy Lab Ltd
Publication of ECSP013952A publication Critical patent/ECSP013952A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Es una fórmula contenida en una tableta diaria para administración oral a humanos para la liberación controlada de Ciprofloxacina, que comprende una cantidad de ciprofloxacina farmacéuticamente efectiva, desde alrededor de 0.1% hasta alrededor de 8.0% de una gente viscolizante y/o un agente de gelación, alrededor de 5.0% hasta alrededor de 15% de un agente generador de gas (efervescencia) y alrededor de 3.0% hasta alrededor de 15% de un agente de expansión, estando dichos porcentajes en relación de peso/peso del compuesto.
EC2001003952A 2000-03-03 2001-03-01 Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina ECSP013952A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51788700A 2000-03-03 2000-03-03

Publications (1)

Publication Number Publication Date
ECSP013952A true ECSP013952A (es) 2002-04-23

Family

ID=24061635

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2001003952A ECSP013952A (es) 2000-03-03 2001-03-01 Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina

Country Status (31)

Country Link
EP (1) EP1263409A1 (es)
JP (1) JP2003525229A (es)
KR (1) KR20030009374A (es)
CN (1) CN1420763A (es)
AP (2) AP2001002084A0 (es)
AR (1) AR032614A1 (es)
AU (1) AU3589701A (es)
BG (1) BG107055A (es)
BR (1) BR0108958A (es)
CA (1) CA2400950A1 (es)
CZ (1) CZ20022883A3 (es)
DO (1) DOP2001000130A (es)
EA (1) EA200200914A1 (es)
EC (1) ECSP013952A (es)
EE (1) EE200200497A (es)
GT (1) GT200100033A (es)
HN (1) HN2001000038A (es)
HR (1) HRP20020715A2 (es)
HU (1) HUP0204417A3 (es)
IL (1) IL151553A0 (es)
IS (1) IS6532A (es)
MX (1) MXPA02008568A (es)
NO (1) NO20024108L (es)
NZ (1) NZ520927A (es)
OA (1) OA12381A (es)
PE (1) PE20011113A1 (es)
PL (1) PL365071A1 (es)
SK (1) SK12542002A3 (es)
WO (1) WO2001064183A1 (es)
YU (1) YU66202A (es)
ZA (1) ZA200206764B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20030229101A1 (en) * 2002-06-06 2003-12-11 Sherman Bernard Charles Tablets comprising ciprofloxacin hydrochloride
DE10351448A1 (de) 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
EP1745775B1 (en) 2005-07-19 2008-05-28 Ethypharm Gastroretentive formulations and manufacturing process thereof.
DE602006012962D1 (de) * 2006-07-19 2010-04-29 Tabuk Pharmaceutical Mfg Co Pharmazeutische Zubereitungen von Ciprofloxacin
EP3247384B1 (en) 2015-01-14 2023-10-04 The Regents of the University of Colorado, a body corporate In vitro method of diagnosis of type 1 diabetes with insulin mimotopes
CA3015400A1 (en) * 2016-02-23 2017-08-31 Matripharm International Inc. Dual-rate release formulation with high drug loading
AU2017236977B2 (en) 2016-03-24 2022-05-26 Immunomolecular Therapeutics, Inc. Methods of treating autoimmune disease
US11052060B2 (en) 2018-02-12 2021-07-06 The Regents Of The University Of Colorado, A Body Corporate Compounds and methods for treating autoimmunity
US11013707B2 (en) 2018-03-23 2021-05-25 The Regents Of The University Of Colorado, A Body Corporate Administration of oral methyldopa
CN109806237A (zh) * 2019-03-13 2019-05-28 悦康药业集团上海制药有限公司 一种乳酸环丙沙星泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5096714A (en) * 1988-06-28 1992-03-17 Hauser-Kuhrts, Inc. Prolonged release drug tablet formulations
JPH0624959A (ja) * 1991-10-04 1994-02-01 Bayer Yakuhin Kk 胃内浮遊型薬物徐放性固形製剤
DE4406424A1 (de) * 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE19839057A1 (de) * 1998-08-28 2000-03-02 Koch Berthold Spülluft-Regler für eine Trockenvorrichtung für Druckluft
NZ510487A (en) * 1998-09-14 2003-04-29 Ranbaxy Lab Ltd Pharmaceutical composition comprising ciprofloxacin, sodium alginate, xanthan gum and a cross-linker polymer in a tablet or capsule form

Also Published As

Publication number Publication date
EP1263409A1 (en) 2002-12-11
BG107055A (bg) 2003-06-30
HUP0204417A3 (en) 2005-03-29
DOP2001000130A (es) 2004-03-31
KR20030009374A (ko) 2003-01-29
YU66202A (sh) 2005-09-19
EA200200914A1 (ru) 2003-02-27
AP2002002627A0 (en) 2002-09-30
GT200100033A (es) 2001-10-25
HUP0204417A2 (en) 2003-05-28
AR032614A1 (es) 2003-11-19
CZ20022883A3 (cs) 2003-04-16
NZ520927A (en) 2003-06-30
IS6532A (is) 2002-08-28
CN1420763A (zh) 2003-05-28
JP2003525229A (ja) 2003-08-26
PL365071A1 (en) 2004-12-27
NO20024108D0 (no) 2002-08-28
EE200200497A (et) 2004-02-16
CA2400950A1 (en) 2001-09-07
WO2001064183A1 (en) 2001-09-07
NO20024108L (no) 2002-10-25
AU3589701A (en) 2001-09-12
HRP20020715A2 (en) 2004-12-31
PE20011113A1 (es) 2001-10-14
ZA200206764B (en) 2003-03-04
IL151553A0 (en) 2003-04-10
HN2001000038A (es) 2005-03-23
SK12542002A3 (sk) 2003-05-02
BR0108958A (pt) 2003-09-30
AP1485A (en) 2005-10-31
AP2001002084A0 (en) 2001-03-31
MXPA02008568A (es) 2003-02-24
OA12381A (en) 2004-09-06

Similar Documents

Publication Publication Date Title
TNSN01130A1 (fr) Formulations a liberation prolongee pour des secretagogues d'hormone de croissance
PE20030602A1 (es) Composicion farmaceutica que comprende un macrolido
ECSP013952A (es) Sistema de administracion oral controlada para la ingestion diaria de ciprofloxacina
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
ATE386508T1 (de) Feste orale dosierungsform enthaltend einen resorptionsverstärker
BR0311867A (pt) Forma de ministração adesiva a mucosa em forma de pelìcula e uso de um extrato ou de um óleo de cannabis para a produção de uma forma de ministração adesiva a mucosa em forma de pelìcula
DE60121570D1 (de) Oral anzuwendende schnell zerfallende feste darreichungsformen
ES2156028T3 (es) Composiciones que contienen tetrahidrolipstatina
HUP9901710A2 (hu) Új stabil gyógyszerkompozíciók hajtógáztól mentes aeroszolok képzésére
HUP0402067A2 (hu) Oltóanyagok
ATE206921T1 (de) Eletriptanhemisulfat und kaffein enthaltende pharmazeutische zusammenstellungen
WO2002038208A3 (en) Device and method for the cessation of smoking
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
PT1267832E (pt) Sistema auto-emulsionante de libertacao de farmaco
CO5280073A1 (es) Composiciones
RS50768B (sr) Režim doziranja i farmaceutska formulacija za urgentnu zaštitu
ATE298324T1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AR021806A1 (es) COMPOSICIoN FARMACÉUTICA EN FORMA DE TABLETA QUE COMPRENDE ENTACAPONA Y MÉTODO DE PREPARACIoN.
DE60115402D1 (de) Neues selbstemulgierendes arzneistoffverabreichungssystem
PT1425005E (pt) Composicao farmaceutica que compreende lumiracoxib
PL402550A1 (pl) Dopochwowe kompozycje farmaceutyczne oraz zastosowanie zródla nadtlenku i bioadhezyjnego nosnika
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
MY129314A (en) Pharmaceutical composition comprising sumatriptan
BR0307320A (pt) Sistema de liberação osmótico
HUP0203148A2 (hu) Mirtazapint tartalmazó orálisan dezintegrálódó készítmény